In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on BIND Therapeutics BIND, but lowered the price target from $21.00 to $20.00.
In the report, Credit Suisse noted, “BIND announced that AMGN declined to exercise its option for BIND's Accurin technology following the completion of the collaboration. We had assigned a low 10% probability to the program so its removal has modest impact to our valuation. We are lowering our TP to $20 from $21.”
BIND Therapeutics closed on Wednesday at $12.88.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in